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Purpose: To evaluate levels of malondialdehyde and the total antioxidant capacity (TAC) in the blood, aqueous humor,
and vitreous bodies of diabetic and nondiabetic patients. We also measured the blood energy charge potential (ECP).
Methods: We examined 19 patients with type 2 diabetes mellitus and diabetic retinopathy. Ten were scheduled for cataract
surgery and pars plana vitrectomy because of proliferative diabetic retinopathy (PDR). The other nine, with mild
nonproliferative PDR (NPDR), and fourteen nondiabetic, age-matched subjects enrolled as a control group were scheduled
for cataract surgery and vitrectomy because of epiretinal membranes. Blood, aqueous humor and vitreous body samples
were collected at the time of surgery. Malondialdehyde concentrations and blood ECP were measured with high-
performance liquid chromatography. The TAC of the samples was estimated with the oxygen radical absorbance capacity
method.
Results: The level of blood and vitreous malondialdehyde in the PDR group was significantly higher compared to controls
and to NPDR patients. PDR patients also had lower levels of TAC at the vitreous body and aqueous humor level, but not
at the blood level, compared to controls and with NPDR patients. In all diabetic patients, the blood ECP values were
significantly lower, compared to control subjects.
Conclusions: Our data support the hypothesis that oxidative stress and the decrease of antioxidant defenses are associated
with the progression of diabetic retinopathy to its proliferative form. Antioxidant supply may have the effect of correcting
oxidative stress and inhibiting disease progression.
In vitro and in vivo studies suggest that oxidative stress
is increased in diabetes and that this plays an important role
in  the  pathogenesis  of  diabetic  complications,  including
retinopathy.  Increased  superoxide  levels  have  been
demonstrated in the retinas of diabetic rats and in retinal cells
incubated in high-glucose media [1,2]. The retinas of rats with
experimentally induced diabetes also display more extensive
membrane lipid peroxidation and oxidative DNA damage,
which  are  the  consequences  of  reactive  oxygen  species
(ROS)-induced injury [1,3-5]. Interestingly, oxidative stress
contributes not only to the onset of diabetic retinopathy, but
also  to  its  persistence  after  glycemic  control  has  been
reestablished.  This  phenomenon,  which  is  referred  to  as
“metabolic  memory”  [6],  has  been  attributed  to  the
accumulation of damaged molecules and ROS that are not
easily eliminated by the restoration of normoglycemia.
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Oxidative  stress  reflects  excess  formation  and/or
impaired removal of ROS. Therefore, adequate levels of the
antioxidant enzymes responsible for scavenging free radicals
are essential for redox homeostasis. Retinal levels of enzymes
such as superoxide dismutase (SOD), glutathione reductase,
glutathione peroxidase, and catalase are decreased in animals
with  experimentally  induced  diabetes  [3,7].  As  a
consequence,  intraretinal  levels  of  the  potent  antioxidant,
glutathione, are also decreased in diabetic rats [8]. In humans,
Pan et al. [9] measured oxidative stress parameters in the
blood, and their findings strengthen the hypothesis that an
increased presence of oxidative species contributes to the
onset  and  advancement  of  diabetic  retinopathy.  However,
apart from this interesting study, very little research has been
done on the oxidative and antioxidant capacities of body fluids
in patients with diabetes or on how these capacities correlate
with the stage of the disease.
To address this issue, we analyzed samples of blood and
aqueous  and  vitreous  humors  from  diabetic  patients  with
proliferative and nonproliferative forms of retinopathy and
nondiabetic controls. Each specimen was subjected to high
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1298performance  liquid  chromatography  (HPLC)  to  determine
levels of malondialdehyde (MDA), which is produced during
phospholipid  peroxidation  [10]  and  the  activation  of  the
arachidonate cycle [11]. MDA is widely regarded as a marker
of  peroxidative  damage  to  cell  membranes  induced  by
physical  or  chemical  oxidative  stress  [12].  The  total
antioxidant  capacity  (TAC)  of  each  sample  was  also
determined  with  the  oxygen  radical  absorbance  capacity
(ORAC) method and according to energy charge potential
(ECP), a biomarker of tissue energy status that was assessed
in blood samples.
METHODS
The study was approved by the institutional review board of
the University Hospital Tor Vergata. The study followed the
tenets of the Declaration of Helsinki. All participants provided
informed consent after receiving an explanation of the nature
and possible consequences of the study. The study group
consisted of 19 patients with type 2 diabetes mellitus (nine
males and ten females; mean age: 72±1.7 years) recruited
from the Ophthalmology Unit of the Tor Vergata University
of Rome Medical Center. All diagnoses of type 2 diabetes
were based on criteria recommended by the World Health
Organization, and all patients were being treated with dietary
measures  and  insulin.  Retinopathy  was  classified  by  an
independent ophthalmologist using fundus photography and
fluorangiographic  imaging.  On  the  basis  of  his  findings,
patients were divided into two groups. Group 1 included ten
patients with mild nonproliferative retinopathy (NPDR), and
group  2  consisted  of  nine  patients  with  proliferative
retinopathy (PDR). The mean duration of diabetes for NPDR
and PDR patients was 16.9±4.2 years and 21.3±6.1 years
respectively. For comparison purposes, we also enrolled a
control  group  consisting  of  14  age-matched  nondiabetic
subjects (6 males and 8 females, mean age 70±2.1 years).
Group 1 patients and control subjects were scheduled for
cataract  surgery  and  vitrectomy  to  eliminate  epiretinal
membranes, with or without macular holes. Group 2 patients
were scheduled for cataract surgery and pars plana vitrectomy
for  long-standing  (>3  months)  or  recurrent  vitreous  or
preretinal hemorrhage, or for tractional retinal detachment
involving  or  threatening  the  macula.  In  this  group,  laser
photocoagulation was performed at an earlier stage of the
disease (but not in the preceding three months) in all patients.
Study candidates were excluded for any of the following
reasons:  smoking,  glaucoma,  liver  disease,  severe
nephropathy,  cancer,  collagen  diseases,  acute  or  chronic
infections,  fever,  congestive  heart  failure,  or  use  of  oral
antioxidant supplements.
Sample collection: Samples of blood, aqueous humor,
and vitreous were collected from all participants on the day of
surgery. Venous blood samples were drawn after an overnight
fast. The samples were placed on ice and centrifuged within
1 h (2,800× g at 4 °C for 15 min), and the supernatants were
stored at −20 °C until analyzed. Aqueous humor samples (0.1–
0.2 ml) were rapidly collected at the beginning of cataract
surgery  with  a  27-gauge  needle  on  a  tuberculin  syringe.
Special care was taken to avoid blood contamination. Samples
were  immediately  cooled  and  stored  at  −70  °C.  Vitreous
humor (300–400 μl) was collected from each patient before
infusion  started.  Samples  were  placed  in  individual  cryo-
Eppendorf tubes, stored at −70 °C, and assayed within 2 weeks
of collection.
Quantitative  analysis  of  malondialdehyde  and  energy
state:  Blood,  aqueous  humor,  and  vitreous  samples  were
collected in sterile tubes. Ice-cold 1.2 M HClO4 (1:2, w/w)
was added to the blood samples to deproteinize erythrocytes.
All samples were centrifuged at 20,690× g for 10 min at 4 °C,
neutralized by adding 5 M K2CO3 in ice, filtered through a
0.45  μM  Millipore-HV  filter  (Millipore  Corporation,
Billerica,  MA),  and  subjected  to  HPLC.  The  ion-pairing
method was used for simultaneous direct determination of
MDA and adenine nucleotide levels in 100 μl of a perchloric
acid  extract  from  each  sample  [12].  We  used  a  Vydac
250×4.6 mm, 5-μm particle size column with its own guard
column  (Eka  Chemicals  AB,  Bohus,  Sweden)  and
tetrabutylammonium hydroxide as the ion-pairing reagent.
Briefly, metabolites were separated by creating a step gradient
(adapted to the column size [12] with two buffers: buffer A
was  10  mM  tetrabutylammonium  hydroxide,  10  mM
KH2PO4, 0.25% methanol, pH 7.00; buffer B was 2.8 mM
tetrabutylammonium  hydroxide,  100  mM  KH2PO4,  30%
methanol, pH 5.50). The gradient was 10 min, 100% buffer
A; 3 min, 90% buffer A; 10 min, 70% buffer A; 12 min, 55%
buffer A; 15 min, 45% buffer A; 10 min, 25% buffer A; and
5 min, 0% buffer A. A flow rate of 1.2 ml/min was maintained
throughout  each  run,  and  the  column  temperature  was
maintained at 23 °C with the aid of water-jacketed glassware.
The  HPLC  apparatus  consisted  of  a  Surveyor  LC  Pump
(ThermoFinnigan Italia, Rodano, Milan, Italy) connected to a
Surveyor  PDA  Detector  (ThermoFinnigan  Italia)  with  a
wavelength range of 200–300 nm. Data were acquired and
analyzed  with  the  ChromQuest  program  (ThermoQuest,
Milan, Italy). Areas, retention times, and absorbance spectra
of the peaks of sample chromatograms were compared with
those of freshly prepared ultrapure standards, to determine the
concentration of the various compounds at 267 nm (the upper
limit  of  the  MDA  absorbance  spectrum)  and  to  identify
different  metabolites.  Hemoglobin  and  the  percentage  of
hemolysis were calculated with standard techniques [13] in a
Jasco-685  double-beam  spectrophotometer  (Jasco  Europe,
Lecco, Italy). Briefly, Hb concentration was determined by
adding 20 μl of whole blood to 5 ml of Drabkin reactive and
measuring  the  absorbance  at  540  nm.  The  percentage  of
hemolysis was determined adding 50 μl of heparinized whole
blood to 5 ml NaCl 0.9% buffered at pH=7.4 and measuring
the absorbance at 540 nm.
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employing ATP, ADP, and AMP (detected by HPLC), and
and  the  ECP  was  calculated  according  to  the  following
formula:  ECP=ATP+0,5  ADP/ΣNT,  where  ΣNT  (=ATP
+ADP+AMP) is the sum of the adenine nucleotide levels
[14].
Oxygen radical absorbance capacity assay: The oxygen
radical absorbance capacity (ORAC) assay is based on the
dose-  and  time-dependent  decrease  in  the  fluorescence
intensity of β-phycoerythrin (β-PE) when oxidized by oxygen
radicals  [15].  It  measures  the  antioxidant  capacity  of  a
substance—blood, vitreous, and aqueous humor in this case
—in terms of its ability to inhibit or delay β-PE peroxidation.
Our assay was performed with the original method [16],
with  a  few  modifications  [17].  AAPH  [2,2’-Azobis(2-
aminopropane)dihydrochloride] purchased from Polyscience
(Warrington, PA) was used as the free radical generator, and
β-PE was purchased from Sigma-Aldrich (St. Louis, MI). The
final reaction mixture (2 ml) contained 1.750 ml of 75 μM
phosphate  buffer  (pH  7.0)  plus  0.100  ml  of  one  of  the
following: 20 μM trolox (6-hydroxy-2,5,7,8-tetramethyl-2-
carboxylic acid), which was used as the standard; a body fluid
sample (blood, aqueous humor, or vitreous); or buffer alone
(used as the reference). Beta-phycoerythrin (0.100 ml of a
34 mg/l solution) was placed in each well, and the oxidant
reaction was started by adding 160 mM (0.050 ml per well)
AAPH. Beta-PE fluorescence was measured with a Varian
Cary  Eclipse  Fluorescence  Spectrofotometer  (Varian
Australian PTY LTD, Victoria, Australia) at λ=546 nm (λ
excitation) and λ=573 nm (λ is emission). Measurements were
made every 2.5 min at 37 °C for 1 h or until the fluorescence
variation dropped below 2%.
The ORAC of the sample was expressed as micromol
trolox equivalents /g and calculated as ([As − Ab]/[At − Ab])
ka, where As is the area under the curve (AUC) of β-PE in the
sample calculated with the Origin 2.8 integrating program
(Microcal Software), At is the AUC of the trolox, Ab is the
AUC of the control, k is the dilution factor (1:500 for the
blood, 1: 100 for aqueous humor, 1:50 for vitreous), and a is
the concentration of the trolox in mmol/l.
Statistical  analysis:  Statistical  analysis  of  differences
between groups was performed with the ANOVA (ANOVA)
test. Significance was set at p<0.05.
RESULTS
As shown in Figure 1, blood MDA levels in diabetic patients
were significantly increased over those of control patients
(p<0.001), due to a highly significant increase of PDR values
versus  control  group  and  versus  NPDR  values  (both,
p<0.001). At the level of the vitreous body, patients with PDR
again had significantly increased MDA levels, compared to
the  controls  (p=0.050),  but  there  were  no  significant
differences between the two groups of diabetic subjects and
controls  or  between  the  NPDR  subgroup  of  patients  and
controls. The analysis of MDA levels in the aqueous humor
revealed no significant differences between any of the groups
tested.
On  the  whole,  the  control  group  also  presented
significantly higher TACs than diabetic subgroups in both the
vitreous (p<0.001) and aqueous humors (p=0.003), but there
were no significant differences in the TACs of blood samples
from these groups (Figure 2). Similar findings emerged from
subgroup analyses. PDR patients had decreased TACs in the
vitreous  and  aqueous  humors  (but  not  in  the  plasma),
compared  to  control  subjects  (p=0.002  and  p=0.003,
respectively) and with the NPDR patient subgroup (p<0.001
and p=0.032, respectively).
The ECP was measured only in the blood samples. On
the  whole,  the  control  group  (mean  0.85±0.04)  exhibited
significantly higher values than the NPDR and PDR groups,
(ANOVA,  p=0.002).  In  this  case,  the  PDR  and  NPDR
subgroups were not significantly different from one another,
and both exhibited mean ECPs (NPDR patients, 0.80±0.05;
PDR patients, 0.79±0.07) that were significantly lower than
the control values (p=0.012 and p=0.016, respectively).
DISCUSSION
In this study, we attempted to characterize the oxidative stress
and the total antioxidant capacities of blood and aqueous and
vitreous  humors  in  diabetic  patients  with  or  without
proliferative retinopathy. Interestingly, in patients undergoing
vitrectomy for PDR, levels of MDA in the blood and vitreous
body (but not in the aqueous humor) were significantly higher
than  those  found  in  nondiabetic  controls  and  in  diabetic
patients with NPDR. Oxidants are highly reactive compounds
with half-lives of a few seconds, and this seriously hinders
their measurement in vivo [9]. However, many biomarkers
have been developed to evaluate oxidative stress, including
the breakdown products of peroxidized polyunsaturated fatty
acids, such as MDA, which has proved to be both sensitive
and  reliable  for  this  purpose  [18].  Ion-pairing  HPLC
performed with tetrabutylammonium allows the simultaneous
measurement  of  all  nucleotides  and  corresponding
deoxynucleosides with no chemical manipulation of samples
other than perchloric acid deproteinization. This approach
minimizes  the  risk  that  metabolite  concentrations  will  be
altered,  and  it  provides  clear,  reliable,  reproducible
information on peroxidative damage and energy metabolism,
both of which are important parameters in studies of ischemia
and reperfusion injury [19]. Increased serum levels of MDA
and  conjugated  dienes  have  been  found  in  patients  with
diabetes  [20],  and  in  a  recent  study  [9],  serum  MDA
concentrations  measured  spectrophotometrically  using  a
thiobarbituric acid-reacting substrate were found to be higher
in patients with PDR than in those with NPDR or in healthy
controls.
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and our findings confirm these previous reports on blood
MDA, and extend this observation to the vitreous body. This
suggests that high blood levels of MDA in diabetic patients
reflect similar increases at the level of the vitreous body, and
it points to the probable involvement of oxidative stress and
lipid peroxidation in the progression of diabetic retinopathy
to the proliferative form. In accordance with this hypothesis,
we also found that patients with PDR had markedly reduced
TACs at the levels of the vitreous (−80% versus controls) and
aqueous (−40%) humors. Because it is relatively difficult to
measure individual antioxidants separately, specific assays
have been designed to measure the overall oxygen radical-
scavenging capacity of fluid samples. The ORAC assay has
been found to provide a good index of the total antioxidant
capacity in patients with diabetes. Studies have shown that the
plasma ORAC is reduced in diabetic patients in general, and
patients with complications such as coronary artery disease
and  renal  failure  have  lower  values  than  those  without
complications [21]. However, reduced blood ORAC values
are strongly associated with poor glycemic control in DM
patients  [21,22],  and  this  may  explain  why  the  ORACs
observed in our patients (with or without retinopathy) were
not  significantly  different  from  those  of  the  nondiabetic
controls.  Verdejo  et  al.  also  suggested  that  antioxidant
defenses in the vitreous body were depressed in patients with
PDR. Their conclusion was based on the results of assays of
SOD activity and catalase levels [23], but the retina has several
other mechanisms for minimizing oxidative stress, including
those involving low molecular weight scavengers (i.e., α-
tocopherol, glutathione, and ascorbic acid) and other enzymes
like  glutathione  peroxidase  [24].  In  addition,  every
antioxidant  system  can  exert  its  activity  with  different
mechanisms  and  different  efficiency,  according  to  its
chemical structure and the stage of the disease. For this reason,
the  TAC  might  be  much  more  important  than  the
concentration of single antioxidants. However, Izuta et al.
[25] recently reported that the TAC of the vitreous is actually
increased  in  patients  with  PDR.  Their  findings  were  not
obtained with the ORAC assay we used with a PAO test,
which  provides  quantitative  estimates  of  the  antioxidant
capacity of a biologic fluid based on the reduction of Cu2+.
Interestingly, we also observed a reduced TAC in the
aqueous humor of patients with PDR. Recent studies have
demonstrated a close correlation between oxidative stress and
morphological changes in the trabecular meshwork [26-28],
suggesting that anterior chamber involvement in patients with
PDR may be caused partly by redox-state imbalances.
Figure  1.  Malondialdehyde  (MDA)
levels in the blood, aqueous humor and
vitreous  of  diabetic  patients  and
controls.  The  levels  of  MDA  were
measured by High Performance Liquid
chromatography in the blood, aqueous
humor and vitreous of the control (white
columns),  non-proliferative  diabetic
retinopathy (NPDR; gray columns) and
proliferative diabetic retinopathy (PDR;
black  columns)  groups.  Blood  MDA
levels  in  PDR  patients  were
significantly  increased  over  those  of
control  and  NPDR  group  (both,
p<0.001).  In  the  aqueous  humor  no
significant  differences  between  the
groups were found. In the vitreous body,
PDR patients, but not NPDR subjects,
had increased MDA levels as compared
with  controls  (p=0.050).  Data  are
expressed  in  µmol/ml  and  represent
mean±standard  deviation  (bars).
ANOVA test was used.
Molecular Vision 2011; 17:1298-1304 <http://www.molvis.org/molvis/v17/a145> © 2011 Molecular Vision
1301Finally,  the  blood  of  our  diabetic  patients  exhibited
significantly reduced energy charge potentials, compared to
controls, and interestingly enough, this difference was not
limited to the patients with proliferative retinopathy. The ECP
represents the balance between energy-producing and energy-
consuming reactions, and decreased values generally reflect
insufficient  production  of  ATP  via  the  oxidative  and
phosphorylative activities of the mitochondria. Our finding
indicates that in diabetic patients, the blood energy supply is
deficient  even  before  the  onset  of  retinopathy,  and  its
reduction may be a primary event in the development of the
complications associated with the disease.
On the whole, these data indicate that alteration of the
redox  state  and  the  energy  potential  contribute  to  the
development  of  diabetic  retinopathy,  although  the
mechanisms by which oxidative stress triggers this event have
not been fully elucidated. Oxidative stress not only creates a
vicious cycle of damage to membrane lipids, proteins, and
DNA, it also amplifies ROS production by also activating
other  metabolic  pathways  that  are  involved  in  the
development of diabetic retinopathy [8]. These include the
polyol pathway [29], the protein kinase C pathway [30,31],
the hexosamine biosynthesis pathway [32], and the advanced
glycation end product pathway [33], the last of which has been
implicated in basement-membrane thickening [34] and the
loss of pericytes and endothelial cells that it causes. ROS are
also known to promote the breakdown of the blood-retinal
barrier  and  to  alter  retinal  blood  flow  by  modulating
production  of  vasoactive  effector  molecules  such  as
endothelin-1  [35].  In  addition,  oxidative  stress  also
upregulates the retinal expression of VEGF [36] and mediates
the hyperglycemia-induced effects of VEGF that give rise to
the microvascular complications of diabetes [37]. Recently,
Izuta [25] found a positive correlation between N-hexanoyl-
lysine (a lipid peroxide) and VEGF concentrations in the
vitreous bodies of patients with PDR, thus confirming that
oxidative stress induced by increased ROS generation may
play a pivotal role in the upregulation of VEGF in the vitreous
body in PDR patients.
The main limitation of our study is the small number of
patients examined, which reflects difficulties in recruiting
patients  with  the  clinical  characteristics  used  as  selection
criteria.
Taken  together,  our  results  strongly  suggest  that  the
development of diabetic retinopathy is associated with high-
level oxidative stress and diminished antioxidant defenses.
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